Literature DB >> 28683206

Changes in mitochondrial properties may contribute to enhanced resistance to ischemia-reperfusion injury in the diabetic rat heart.

Martina Muráriková1, Miroslav Ferko1, Iveta Waczulíková2, Magdaléna Jašová1, Ivana Kancirová1, Jana Murínová3, Táňa Ravingerová1.   

Abstract

Diabetes mellitus, besides having deleterious effects, induces cardiac adaptation that may reduce the heart's susceptibility to ischemia-reperfusion (IR) injury. This study aimed to investigate whether changes in mitochondrial properties are involved in the mechanisms of increased resistance of the diabetic heart to IR. Adult male Wistar rats were made diabetic by a single dose of streptozotocin (65 mg·kg-1, i.p.), and on the day 8, Langendorff-perfused hearts were subjected to 30 min global ischemia and 40 min reperfusion. Baseline preischemic parameters in the diabetic hearts did not differ markedly from those in the nondiabetic controls, except for lower left ventricular developed pressure, higher mitochondrial membrane fluidity, and protein levels of manganese superoxide dismutase. On the other hand, diabetic hearts showed significantly better post-IR functional restoration and reduced arrhythmogenesis associated with lower reactive oxygen species production as compared with healthy controls. IR decreased membrane fluidity in both experimental groups; however, it led to a complete recovery of mitochondrial Mg2+-ATPase activity in diabetics in contrast to its reduction in nondiabetics. These findings indicate that the heart may become adapted to diabetes-induced alterations that might increase its tolerance to an ischemic insult. Preserved mitochondrial function might play a role in the mechanisms of the heart's resistance to IR injury in diabetics.

Entities:  

Keywords:  Mg2+-ATPase mitochondriale; adaptation; diabète provoqué par la streptozotocine; fluidité membranaire; ischemia–reperfusion; ischémie–reperfusion; membrane fluidity; mitochondrial Mg2+-ATPase; streptozotocin-induced diabetes

Mesh:

Substances:

Year:  2017        PMID: 28683206     DOI: 10.1139/cjpp-2017-0211

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

1.  Risk Factors of Ischemia Reperfusion Injury After PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction and its Influence on Prognosis.

Authors:  Li Zhang; Lingqing Wang; Luyuan Tao; Changgong Chen; Shijia Ren; Youyou Zhang
Journal:  Front Surg       Date:  2022-06-07

Review 2.  Myocardial Adaptation in Pseudohypoxia: Signaling and Regulation of mPTP via Mitochondrial Connexin 43 and Cardiolipin.

Authors:  Miroslav Ferko; Natália Andelová; Barbara Szeiffová Bačová; Magdaléna Jašová
Journal:  Cells       Date:  2019-11-17       Impact factor: 6.600

3.  Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia-reperfusion injury in type 1 diabetes mellitus.

Authors:  Wei Li; Jianxin Xu; Xin Guo; Xinhua Xia; Yanling Sun
Journal:  Exp Ther Med       Date:  2021-02-08       Impact factor: 2.447

4.  Dichloroacetate as a metabolic modulator of heart mitochondrial proteome under conditions of reduced oxygen utilization.

Authors:  Natalia Andelova; Iveta Waczulikova; Lukas Kunstek; Ivan Talian; Tanya Ravingerova; Magdalena Jasova; Simon Suty; Miroslav Ferko
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

5.  mPTP Proteins Regulated by Streptozotocin-Induced Diabetes Mellitus Are Effectively Involved in the Processes of Maintaining Myocardial Metabolic Adaptation.

Authors:  Natalia Andelova; Iveta Waczulikova; Ivan Talian; Matus Sykora; Miroslav Ferko
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

Review 6.  The Molecular Mechanisms of Iron Metabolism and Its Role in Cardiac Dysfunction and Cardioprotection.

Authors:  Tanya Ravingerová; Lucia Kindernay; Monika Barteková; Miroslav Ferko; Adriana Adameová; Vladislava Zohdi; Iveta Bernátová; Kristina Ferenczyová; Antigone Lazou
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.